Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBeyond Air Inc

Beyond Air Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
2.1643 USD -0.02 ( 0.72%)
Last update at 2026-11-06T20:56:00Z
VOLUME
17249
Market Cap
3.08M

Momentum Score

…

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.14
Low
2.25
High
52 Week Price Range
3.06
Low
55.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.18
Dividend Yield
-
Revenue TTM
7.69M
Revenue Per Share
14.43
Gross Profit TTM
0.32M
Debt / Equity
3.82
ROE
-519.51%
Net Debt
16.64M
ROCE
-118.91%
Diluted EPS TTM
-60.53

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -34.33M -48.48M -64.30M -59.40M -44.06M
Minority interest 1.08M 1.85M 4.05M -3.58M -0.88M
Net income -33.25M -46.62M -60.24M -55.82M -43.18M
Selling general administrative 19.05M 26.02M 37.34M 34.69M 18.41M
Selling and marketing expenses - - 0.60M - -
Gross profit 0.25M -1.66M -1.31M -0.56M -0.59M
Reconciled depreciation 3.65M 3.57M 2.35M 1.17M 0.35M
Ebit -34.33M -45.46M -61.38M -52.06M -30.21M
Ebitda -31.23M -41.89M -59.03M -50.89M -29.62M
Depreciation and amortization 3.10M 3.57M 2.35M 1.17M 0.59M
Non operating income net other - - - -7.31M -2.58M
Operating income -29.04M -44.54M -63.01M -51.50M -40.71M
Other operating expenses 36.72M 48.24M 64.17M 52.06M 30.21M
Interest expense 3.52M 3.02M 2.91M 0.03M 0.78M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -3.52M -3.02M -2.91M -0.03M -0.78M
Income tax expense -1.08M - -4.05M -3.56M -0.11M
Total revenue 7.68M 3.71M 1.16M 0.06M 0.15M
Total operating expenses 29.30M 42.87M 61.70M 51.50M 30.21M
Cost of revenue 7.43M 5.37M 2.47M 0.56M 0.59M
Total other income expense net -5.29M -3.94M -1.29M -7.31M -13.07M
Net income from continuing ops -34.33M -48.48M -64.30M -59.40M -44.06M
Net income applicable to common shares - - - -55.82M -43.18M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 35.38M 30.06M 56.96M 68.75M 99.20M
Intangible assets 1.02M 1.22M 1.43M 1.63M 1.84M
Other current assets 10.53M 5.82M 6.79M 0.34M 0.51M
Total liab 29.18M 15.72M 29.77M 26.72M 20.99M
Total stockholder equity 6.13M 13.58M 25.05M 37.91M 72.70M
Other current liab 3.37M 2.04M 8.26M -0.00M 8.38M
Common stock 0.00M 0.01M 0.01M 0.00M 0.00M
Capital stock 0.00M 0.01M 0.01M 0.00M 0.00M
Retained earnings -319.57M -286.32M -239.70M -179.46M -123.64M
Other liab - - - - 8.00M
Other assets - - 0.00M -0.00M 0.21M
Cash 6.74M 4.67M 11.38M 29.16M 80.24M
Total current liabilities 6.51M 5.00M 11.57M 19.78M 10.71M
Current deferred revenue - - 0.14M 16.61M -
Net debt 16.64M 7.02M 6.46M -25.57M -76.75M
Short term debt 0.72M 1.00M 1.22M 1.15M 1.21M
Short long term debt 0.40M 0.61M 0.80M 0.78M 0.93M
Short long term debt total 23.38M 11.69M 17.84M 3.59M 3.49M
Other stockholder equity 325.56M 299.96M 264.75M 217.31M 196.24M
Property plant equipment - - - 5.00M 2.00M
Total current assets 24.77M 16.02M 43.94M 59.41M 92.94M
Net tangible assets - - - 37.91M 72.70M
Short term investments 4.90M 2.25M 23.09M 16.72M -
Net receivables 1.19M 0.86M 0.55M 0.65M 0.60M
Long term debt 21.64M 9.20M 14.72M 4.62M 8.20M
Inventory 1.41M 2.42M 2.13M 1.13M 0.35M
Accounts payable 2.42M 1.95M 1.95M 2.02M 1.13M
Noncontrolling interest in consolidated entity - - - 4.11M 5.50M
Accumulated other comprehensive income 0.13M -0.06M -0.01M 0.05M 0.10M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -179.46M -123.64M
Treasury stock - - - -0.03M -0.03M
Non currrent assets other 0.16M 0.10M 0.11M 0.21M 0.21M
Non current assets total 10.62M 14.04M 13.03M 9.34M 6.25M
Capital lease obligations 1.34M 1.88M 2.32M 2.70M 2.36M
Long term debt total - - - 4.62M 8.20M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments -2.65M 14.90M -12.23M -16.71M -1.45M
Change to liabilities - - - 5.63M 4.55M
Total cashflows from investing activities -3.67M 14.90M -12.23M -20.59M -1.45M
Net borrowings 13.79M -6.73M 14.98M -1.01M 0.37M
Total cash from financing activities 29.09M 16.65M 43.17M 2.70M 79.45M
Change to operating activities - - - 5.34M 12.16M
Net income -33.25M -48.48M -60.24M -59.40M -44.06M
Change in cash 7.47M -6.71M -27.68M -50.94M 54.96M
Begin period cash flow 4.90M 11.61M 39.29M 90.23M 35.27M
End period cash flow 12.36M 4.90M 11.61M 39.29M 90.23M
Total cash from operating activities -18.14M -38.22M -56.02M -33.01M -23.13M
Issuance of capital stock 13.34M 23.01M 27.97M 3.71M 72.83M
Depreciation 3.44M 3.57M 2.35M 1.17M 0.35M
Other cashflows from investing activities - 0.01M - 0.00M -0.07M
Dividends paid - - - - 11.14M
Change to inventory 1.11M -0.47M -1.00M -0.78M -0.78M
Change to account receivables -0.47M -0.39M 0.10M -0.10M 0.10M
Sale purchase of stock - - 14.59M 3.71M 11.14M
Other cashflows from financing activities 29.09M 0.36M 0.22M 2.70M 7.28M
Change to netincome - - - 19.83M 7.97M
Capital expenditures 1.02M 5.88M 5.75M 3.88M 1.45M
Change receivables - - - -0.10M 0.10M
Cash flows other operating - - - 0.97M 7.99M
Cash and cash equivalents changes - - - -50.90M 54.87M
Change in working capital 2.35M -6.15M -16.04M 5.39M 11.83M
Stock based compensation 5.28M 9.15M 21.34M 19.56M 7.83M
Other non cash items 4.03M 3.70M 17.91M -0.00M 0.91M
Free cash flow -19.17M -44.10M -61.76M -36.89M -24.58M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
XAIR
Beyond Air Inc		 -0.02
0.72%		 2.16 - - 0.40 1.56 2.20 -4.23
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Beyond Air Inc

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

900 Stewart Avenue, Garden City, NY, United States, 11530

516 665 8200

https://www.beyondair.net

54

Name Title Year Born
Mr. Steven Adam Lisi CEO & Chairman 1971
Mr. Amir Avniel Co-Founder, Chief Bus. Officer & Director 1974
Mr. Douglas Quinton Larson CFO, Principal Financial Officer & Principal Accounting Officer 1971
Mr. Michael A. Gaul Chief Operating Officer 1955
Edward Barger Head of Investor Relations NA
Mr. Adam Newman Chief Legal Officer & Gen. Counsel NA
Ms. Rebecca Van Doren Head of Sales NA
Ms. Kori-Ann Taylor Head of Marketing NA
Prof. Andrew R. Colin M.D. Chief Medical Officer & Member of Scientific Advisory Board NA
Dr. Giora Davidai M.D. Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…